

**25 OCTOBER 2021**

# **PRESENTATION AT SOUTH-WEST CONNECT ASX SHOWCASE**

## **ASX ANNOUNCEMENT**

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce its participation in the Canaccord Genuity South-West Connect ASX Showcase, to be held on Wednesday 27 & Thursday 28 October 2021 at Abbey Beach Resort, Busselton WA.

LGP’s Chief Operating Officer, Paul Long, will be presenting at the event on Wednesday 27 October at 10.30am (AWST).

The Company’s presentation will focus on the growth of the LGP business in Australia and globally over the past 24 months, the expansion of its Australian operations, its acquisition of its GMP production facilities in Denmark, and future growth plans.

Attendance at the event is free. Investors wishing to physically attend the event can register here:

<https://www.southwestconnect.com.au>.

The event is also being livestreamed via Zoom. Attendees can pre-register for the event here:

[https://us02web.zoom.us/webinar/register/WN\\_NFME9YfYQhS5JbyOZGz\\_EA](https://us02web.zoom.us/webinar/register/WN_NFME9YfYQhS5JbyOZGz_EA)

LGP will also make available a recorded copy of its presentation on its investor website after the event:

<https://investor.littlegreenpharma.com/site/investor-centre/presentations>

**ENDS**



**BY ORDER OF THE BOARD**

A handwritten signature in black ink, appearing to read "Alistair Warren".

**Alistair Warren**  
Company Secretary

**For further information please contact:**

**Alistair Warren**  
Company Secretary  
Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +61 8 6280 0050

**Fleta Solomon**  
Managing Director  
Little Green Pharma  
E: [f.solomon@lgp.global](mailto:f.solomon@lgp.global)  
T: +61 8 6280 0050



**About Little Green Pharma**

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m<sup>2</sup> cultivation and 4,000m<sup>2</sup> GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility over located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. The Company is also licensed to supply psilocybin and is presently expanding its WA production facilities to produce psilocybin medicines.

Little Green Pharma cannabis products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

**Help us be Green**

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)

For personal use only